While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

For patients with higher-risk myelodysplastic syndromes (MDS), what are some of the primary challenges in conducting research and developing novel therapies for this patient population? How do social ...

(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) Wednesday said the Food and Drug Administration or FDA has granted orphan drug designation to the company's drug candidate tebapivat for the treatment of ...

Video content above is prompted by the following: What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and ...

Agios on Wednesday said the designation covers tebapivat for the treatment of myelodysplastic syndromes, or MDS, in which immature blood cells in the bone marrow don't mature or become healthy blood ...

Mitapivat, the company’s lead PK activator, was previously granted FDA orphan drug designation for the treatment of PK deficiency, thalassemia, and sickle cell disease. Tebapivat is not approved for ...

Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk ...

Dr Andrew Ross, a medical doctor diagnosed with a life-threatening condition called Myelodysplastic Syndrome (MDS) is ...

McKesson Corporation MCK is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The ...

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted ...